齊忠權,男,1960年出生,教授,瑞典隆德大學博士畢業。研究方向為移植免疫,免疫排斥機理。學科專長為器官移植抗排斥對策及免疫細胞信號傳導機制。
基本介紹
- 中文名:齊忠權
- 國籍:中國
- 出生日期:1960年
- 職業:教授
- 畢業院校:哈爾濱醫科大學
- 主要成就:盧嘉錫導師獎
- 代表作品:《活體供腎腎臟移植臨床規範》
簡介,學習與工作經歷,獲 獎 情況,學術專長,科研成果,主持科研項目,專利情況,專著情況,論著情況,
簡介
齊忠權,教授、博士生導師,瑞典隆德大學博士畢業。現任廈門大學器官移植研究所所長、廈門大學醫學院副院長、廈門大學醫院執行院長,同時兼任哈爾濱醫科大學教授、博士生導師、國際器官移植協會會員、國務院僑辦第二屆海外諮詢委員會委員、福建省器官移植協會副主任委員、廈門市醫學會常務理事。
學習與工作經歷
教 育 情況
1979-1984 哈爾濱醫科大學醫療系讀大學
1994-1999 瑞典隆德大學醫學院讀博士
1999-2001 瑞典隆德大學馬爾默醫院博士後
工 作 經歷
1984-1991 哈爾濱醫科大學附屬第一醫院外科:住院醫師和助教
1991-1993 哈爾濱醫科大學附屬第一醫院外科:主治醫師和講師
1993-1999 瑞典隆德大學馬爾默醫院外科:外科博士,客座醫生
1999-現在 瑞典隆德大學馬爾默醫院移植外科:研究員,移植專家
2000-現在 哈爾濱醫科大學,教授。
2003-現在 哈爾濱醫科大學博士生導師
2005-現在 廣西醫科大學名譽教授
2008-現在 廈門大學醫院院長。
獲 獎 情況
1991 黑龍江省科技進步一等獎:“部分脾臟切除術”
1993 黑龍江省科技進步一等獎:“世界首例父子間異體劈裂脾移植”
1995 瑞典科技年會獎:“抗CD4單克隆抗體對大鼠心臟移植的抗排研究”
2006 2006年入典美國醫學衛生保健世界名人傳記《Who’s Who In Medicine And Healthcare》第7版年鑑。
2008 福建省高校優秀共產黨員、廈門市五一勞動獎章、中國醫師獎提名獎
2011 盧嘉錫導師獎
學術專長
齊忠權教授從事外科臨床、科研工作近20餘年,在普通外科學、腹部臟器移植學、移植免疫以及免疫抑制劑開發等領域有很深造詣,參加過500餘例的人體腎臟、肝臟、胰腺移植手術,迄今已發表SCI論文近40篇,最高影響因子7.1。
科研成果
一、改良器官移植實驗外科技術。齊忠權教授對動物移植模型進行了改良,創造了出袖套法小鼠心臟移植模型、小鼠小腸移植模型等新實驗外科技術。
二、開發和篩選新型免疫抑制劑。齊忠權教授他在全世界首先闡明了免疫抑制劑MNA715和MNA279(來夫米啶衍生物)的完整分子式,並曾在歐洲某大型醫藥公司中主持過新型免疫抑制劑的篩選工作。近年來,通過與廣西醫科大學合作,從板藍根中成功提取出了一種具免疫抑制和抗腫瘤作用的單體。
三、深入器官移植臨床工作。齊忠權教授在瑞典和土耳其等國主持以及參加的器官移植手術超過500餘例,臨床經驗十分豐富。
四、移植免疫相關研究。齊忠權教授有深厚的科研積累,在學界內有一定影響力。
主持科研項目
在瑞典期間,主持的課題主要有:
⑴ The development of new compounds which inhibit the acute rejection using rat heart transplant model. (Active Biotech AB,Lund,Sweden2001-2004) 經費150,000美元
⑵ Tutor for the international course of microsurgery,and scientific adviser (DiLab,Lund,Sweden 2003-2006) 經費30,000美元
⑶ Initial inhibition of tissue factor signalling reduces chronic vascular changes in isogenic rat aortic transplants. (Novo Nordisk,Denmark 2003-2006) 經費60,000美元
回國後,主持的課題主要有:
⑴ 活體腎臟移植的系列研究
(廈門大學科研啟動經費 2007-2011)經費300萬人民幣
⑵ 胰島細胞和腎臟移植治療糖尿病腎病的研究
(福建省衛生科技聯合攻關項目 2008-2011)經費30萬人民幣
⑶ 抗CD40-L和抗LFA-1單抗在預防異種胰島移植排斥中的作用
(廈門市科技項目 2009-2011)經費10萬人民幣
⑷ 板藍根組酸單體抗腫瘤及抗器官移植排斥雙重作用的研究
(福建省科技重點項目2010-2013)經費15萬人民幣
專利情況
高級脂肪酸衍生物類新化合物及其製備方法和抗腫瘤用途
專利公開號:CN101475506A
專著情況
《活體供腎腎臟移植臨床規範》
作者:齊忠權 Henrik Ekberg(瑞典)
Wolters Kluwer Health Co.Ltd 於2009年12月出版
論著情況
Junjie Xia,1 Jibing Chen,2 Wei Shao,1 Tianshu Lan,1 Yongzhi Wang,1 Baiyi Xie,1 Henrik Thorlacius,3 Feng Tian,2 Ruxin Huang,4 Zhongquan Qi,Suppressing memory T cell activation induces islet allograft tolerance in alloantigen-primed mice. Transplant International. (*通訊作者)(accepted 2010)Feng Wang,JibingChen,WeiShao,Baiyi Xie,YongzhiWang,TianshuLan,HenrikThorlacius,Zhongquan Qi. Anti-CD44 Monoclonal Antibody Inhibits Heart Transplant Rejection Mediated by Alloantigen-primed CD4+Tm in Nude Mice. Transplant Immunology. (*通訊作者)(accepted 2010)Lan Tianshu,Chen Jibing,Kang Xiangpeng,Wang Feng,Wang Yongzhi,Xia Junjie,Qi Zhongquan. Pre-contact of tolerance circumstance protect the allograft from attacking by memory T cells. Scandinavian Journal of Immunology(*通訊作者)(accepted 2010)Xiangpeng Kang,Jibing Chen,Qing Qin,Feng Wang,Yongzhi Wang,Tianshu Lan,Shuo Xu,Feiyu Wang,Junjie Xia,Henrik Ekberg,Zhongquan Qi,Zhongchen Liu.Isatis tinctoria L. combined with co-stimulatory molecules blockade prolongs survival of cardiac allografts in alloantigen-primed mice. Transpl Immunol. (*通訊作者)(accepted 2010)Baiyi Xie,Jibing Chen,Feng Wang,Tianshu Lan,Yongzhi Wang,Junjie Xia,Zhi Li,Qingxiang Xie,Ruxin Huang,Zhongquan Qi. Monoclonal Antibody Treatment to Prolong the Secondary Cardiac Allograft Survival in Alloantigen-primed Mice. Scandinavian Journal of Immunology. (*通訊作者)(accepted 2010)Liang H,Liao C,Qi Z,Sha C,Xie B,Chen J,Xia J,Wang Y,Yao Q,Zhao Y. Rapamycin or tacrolimus alone fails to resist cardiac allograft accelerated rejection mediated by alloreactive CD4(+) memory T cells in mice. Transpl Immunol. 2009; [Epub ahead of print]Hua Liang,Yongxiang Zhao,Zhonggui San,Chongxian Liao,Chuang Sha,Baiyi Xie,Jibing Chen,Junjie Xia,Yongzhi Wang,Zhongquan Qi(通訊作者). The recall alloresponse following retransplantation is more intense compared with the T cell memory-transfer model.Immunol Invest,2010 (accepted,manuscript ID: LIMM-2009-0045)Zhao Y,Zhang S,Zhou J,Wang J,Zhen M,Liu Y,Chen J,Qi Z*. The Development of a Tissue-Engineered Artery Using Decellularized Scaffold and Autologous Ovine Mesenchymal Stem Cells. Biomaterials 2009 Oct ; 31:296–307.(IF=6.6) (*通訊作者)Chen X,Shao W,Chen J,Zhang L,Corbascio M,Shi-Guang S and Qi Z*. Allotransplantation of Sulphate Glucomannan-Alginate Barium (SGA) –Microencapsulated Rat Islets for the Treatment of Diabetes Mellitus. Immunological investigation 2009 July; 38:1-11. (*通訊作者)Xie B,Chen J,Xia J,Wang Y,Liang H,Henrik E,Matthias C and Qi Z*. Combined Costimulation Blockade Inhibits Accelerated Rejection Mediated by Alloantigen-Primed Memory T cells in Mice. Immunological investigation 2009 Oct;38:1-13. (*通訊作者)Wang Y,Chen J,Qin Q,Kuang X,Xia J,Xie B,Wang F and Qi Z*. Synergistic Effects of Isatidis and Tacrolimus in the Prevention of Acute Heart Rejection in Mice. Transplantation immunology 2009 Sep;22:5-11. (*通訊作者)Eriksson T,Wallin R,Hoglund P,Roth B,Qi Z,Ostraat O,Bjorkman S. Low bioavailability of rectally administered thalidomide. Am J Health Syst Pharm.2000 ; 57⒄: 1607-10.Oderup C,Malm H,Ekberg H,Qi Z,Veress B,Ivars F,Corbascio M. Costimulation blockade-induced cardiac allograft tolerance: inhibition of T cell expansion and accumulation of intragraft cD4(+)Foxp3(+) T cells. Transplantation. 2006 15; 82⑾: 1493-500.Zhang L,Qi Z,Shan S,Wu D,Sun Y,Ekberg H. The effects of leflunomide and FK 506 on rejection of xenografts in rat-to-mouse. Scand J Immunol. 2004; 59⑶: 255-60.Zaina S,Pettersson L,Thomsen AB,Chai CM,Qi Z,Thyberg J,Nilsson J. Shortened life span,bradycardia,and hypotension in mice with targeted expression of an Igf2 transgene in smooth muscle cells. Endocrinology 2003 ; 144⑹: 2695-703. Corbascio M,Mahanty H,Osterholm C,Qi Z,Pearson TC,Larsen CP,Freise CE,Ekberg H. Anti-lymphocyte function-associated antigen-1 monoclonal antibody inhibits CD40 ligand-independent immune responses and prevents chronic vasculopathy in CD40 ligand-deficient mice. Transplantation 2002 ;74⑴:35-41.Corbascio M,Ekstrand H,Osterholm C,Qi Z,Simanaitis M,Larsen CP,Pearson TC,Riesbeck K,Ekberg H. CTLA4Ig combined with anti-LFA-1 prolongs cardiac allograft survival indefinitely. Transpl Immunol. 2002 ; 10⑴: 55-61.Österholm C,Qi Z,Ekberg J,Veress B,Pyke C,Hedner U,Ekberg H. Initial inhibition of tissue factor signalling reduces chronic vascular changes in isogenic rat aortic transplants. Am J Transplantation 2001 ; 1⑴: 29-37.Eriksson T,Wallin R,Hoglund P,Roth B,Qi Z,Ostraat O,Bjorkman S. Low bioavailability of rectally administered thalidomide. Am J Health Syst Pharm.2000 ; 57⒄: 1607-10.M Olausson,D Lukes,J Norrby,Qi Z,Ekberg H,Gannedahl G,Tufvesson G,Mjörnstedt L. Antithymocyte Globulin and Cyclosporine A are Synergistic in an Experimental Transplantation Tolerance Model in the Rat. Scand J Immunol .1999; 49⑴: 38-44.Qi Z,Tufveson G,Ekberg H. Tolerance or rejection : A delicate balance as judged by exposure of heart-transplanted rats to the immunomodulator Linomide. Scand J Immunol. 1999; 50⑷: 394-8.Qi Z,Simanaitis M,Ekberg H. Malononitrilamides and tacrolimus additively prevent acute rejection in rat cardiac allografts.Transpl Immunol. 1999; 7⑶: 169-75.Östraat Ö,Qi Z,Tufveson G,Hedlund G,Ekberg H. The effects of leflunomide and cyclosporin A on rejection of cardiac allograft in rat. Scand.J.Immuno. 1998; 48⑷: 379-88.Petersson E,Qi Z,Hedlund G,Ekberg H. Activation of donor-specific CTL in a tolerant recipient of cardiac allograft. Cell Immunol. 1998; 189⑴:19-24.Qi Z,Ekberg H. Malononitrilamides prevent and suppress allospecific antibody production. Transplant Proc. 1998 ; 30⑻: 3980. Qi Z,Ekberg H. Malononitrilamides 715 and 279 prolong rat cardiac allograft survival,reverse ongoing rejection,inhibit allospecific antibody production and interact positively with cyclosporin. Scand J Immunol. 1998; 48⑷: 379-88.Qi Z,Simanaitis M,Ekberg H. Malononitrilamides 715 and 279 prevent accelerated cardiac allograft rejection synergistically with cyclosporin A in presensitized rats. Transpl Immunol. 1998; 6⑵: 94-100.Östraat Ö,Qi Z,Olausson M,Tufveson G,Ekberg H. Mycophenolate mofetil,azathioprine and cyclophosphamide enhanced efficacy combined with cyclosporine in rat cardiac transplantation. Scand J Immunol. 1997; 45⑷: 343-8.Petersson E,Qi Z,Ekberg H,Ostraat O,Dohlsten M,Hedlund G. Activation of alloreactive natural killer cells is resistant to cyclosporine. Transplantation 1997 27; 63⑻: 1138-44.Qi Z,Riesbeck K,Östraat Ö,Tufvesson G,Ekberg H. Single dose anti-CD4 monoclonal antibody therapy for induction of tolerance to cardiac allografts in high- and low-responder rat strains. Transpl Immunol. 1997; 5⑶: 204-11.. Bjorkman S,Fyge A,Qi Z. Determination of the steady state tissue distribution of midazolam in the rat. J Pharm Sci. 1996; 85⑻: 887-9.Östraat Ö,Riesbeck K,Qi Z,Eriksson T,Schatz H,Ekberg H. Thalidomide prolonged graft survival in a rat cardiac transplant model but had no inhibitory effect on lymphocyte function in vitro. Transpl Immunol. 1996 ; 4⑵: 117-25.33. Bojrup M,Qi Z,Bjorkman S,et al. Bioavailability of cyclosporine in rats after intragastric administration: a comparative study of the L2-phase and two other lipid-based vehicles. Transpl Immunol. 1996; 4⑷: 313-7
Östraat Ö,Qi Z,Olausson M,Gannedahl G,Tufveson G,Ekberg H. Additive immunosuppressive effect of combined mycophenolate mofetil and cyclosporin A in experimental rat cardiac transplantation. Transplant Proc.1995; 27⑹: 3540.Östraat Ö,Qi Z,Gannedahl G,Tufveson G,Ekberg H. Moderate additive immunosuppressive effect of thalidomide combined with cyclosporin A in rat cardiac transplantation. Transpl Immunol. 1996; 4⑶: 241-6.姜洪池; 李廣華; 吳業權; 曲英貴; 單世光; 齊忠權; 劉傑; 武林楓; 王阿麗; 夏穗生。脾被膜移植的規則性部分脾切除術(附18例報告)。中華實驗外科雜誌,1991,(03).張樹才,單世光,宋東,齊忠權,洪大衛,薛興文,侯全吉,魏林玉。對脾手術若干問題的探討。哈爾濱醫科大學學報,1992,(03).齊忠權,單世光,王國卿,姜洪池,李智勛,吳業權,李廣華。部分脾切除術脾斷面處理的實驗研究。中華實驗外科雜誌 ,1992,9⑴喬海泉,單世光,姜洪池,齊忠權,吳業權,張樹才,侯利民。非門脈相續性部分脾臟移植的研究。中華實驗外科,1994,11⑴